Shingles vaccines comprising a TLR9 agonist
US-12569553-B2 · Mar 10, 2026 · US
Demonstrated in vivo effect
Demonstrated in vivo effect · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C12N2710/16771 |
| Official title | Demonstrated in vivo effect |
| Display label | Demonstrated in vivo effect |
| Total patents | 29 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is rapidly growing.
| Year | Patents |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 7 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Truncated varicella-zoster virus envelope glycoprotein ge
US-2025236646-A1 · Jul 24, 2025 · US
Nucleic acid vaccines for varicella zoster virus (vzv)
US-2025188132-A1 · Jun 12, 2025 · US
Immunogenicity of a cpg-adjuvanted herpes zoster vaccine
US-2025163105-A1 · May 22, 2025 · US
Bovine herpesvirus type 1 (BoHV-1) vector against bovine respiratory disease complex
US-12296003-B2 · May 13, 2025 · US
Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US-2024270796-A1 · Aug 15, 2024 · US
Nucleic acid vaccines for varicella zoster virus (vzv)
US-2023374079-A1 · Nov 23, 2023 · US
Nucleic acid vaccines for varicella zoster virus (vzv)
US-2023303632-A1 · Sep 28, 2023 · US
Genetically Modified Bovine Herpesvirus Type 1 (BHV-1) for use to Treat Cancer
US-2023233630-A1 · Jul 27, 2023 · US
Nucleic acid vaccines for varicella zoster virus (VZV)
US-11643441-B1 · May 9, 2023 · US
Shingles vaccines comprising a tlr9 agonist
US-2023061403-A1 · Mar 2, 2023 · US
Dry liposome adjuvant-containing vaccines and related methods thereof
US-2023060631-A1 · Mar 2, 2023 · US
Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US-11572389-B2 · Feb 7, 2023 · US
Cationic oil-in-water emulsions
US-11167028-B2 · Nov 9, 2021 · US
Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US-2021163542-A1 · Jun 3, 2021 · US
Immunostimulatory plasmids
US-10851379-B2 · Dec 1, 2020 · US
Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US-2019367561-A1 · Dec 5, 2019 · US
Liposomal adjuvant compositions
US-10456459-B2 · Oct 29, 2019 · US
Cationic oil-in-water emulsions
US-2019091329-A1 · Mar 28, 2019 · US
Cationic oil-in-water emulsions
US-10183074-B2 · Jan 22, 2019 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C12N2710/16771?
- CPC C12N2710/16771 is the Cooperative Patent Classification code for “Demonstrated in vivo effect.”
- How many patents are filed under CPC C12N2710/16771 (Demonstrated in vivo effect)?
- Our database includes 29 publications tagged with this CPC code.
- Is patent activity under CPC C12N2710/16771 growing?
- Publication counts under this code: 1 in 2024 vs 4 in 2025 (latest complete years).